Abstract
Clinical and epidemiological investigations confirm that patients with loss-of-function mutations (R19X, etc.) in Apolipoprotein CIII (ApoCIII) showed beneficial lipid profile including decreased plasma triglyceride and increased high density lipoprotein (HDL) levels. However, whether HDL level would be reduced in hypertriglyceridemia (HTG) induced by high ApoCIII expression has not been demonstrated yet. Here we showed, ApoCIII transgenic mice (ApoCIIItg) displayed severe HTG and had significantly lower HDL level. Analysis of apolipoproteins in lipoprotein fractions by SDS-PAGE revealed marked decrease of apolipoprotein AI (ApoAI) in HDL in transgenic mice compared with the wild type mice (WT) as controls. Further examination demonstrated that hepatic but not intestinal ApoAI mRNA was significantly reduced. Therefore, the decreased ApoAI synthesis might be accounted for the lower plasma HDL level in ApoCIII transgenic mice.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
